Warrior CARE: Cannabis Behavioral Health (CBH)

Wayne State University logo

Wayne State University

Status and phase

Not yet enrolling
Phase 2
Phase 1

Conditions

Veterans
Post Traumatic Stress Disorder
Cannabis Use
Suicide
Marijuana

Treatments

Drug: Placebo
Drug: Cannabidiol
Drug: Tetrahydrocannabinol

Study type

Interventional

Funder types

Other

Identifiers

NCT06381180
Warrior CARE: CBH

Details and patient eligibility

About

This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.

Full description

In this clinical trial, we will recruit veterans with PTSD who report using cannabis or have interest in trying cannabis for symptom relief. Veterans will be randomized into one of four different groups: THC (∆9-tetrahydrocannabinol), CBD (cannabidiol), THC+CBD, and Placebo, and undergo a 12-week treatment phase where they will be asked to vaporize their assigned cannabis dose every day for 12 weeks. Participants will complete weekly questionnaires regarding their mood, behavior and drug consumption. Furthermore, there is a laboratory component that will assess cognition, fear conditioning, and other PTSD-related measures.

Enrollment

500 estimated patients

Sex

All

Ages

19 to 69 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • able to provide informed consent, IQ Score >80,
  • served in branch of the US armed forces, report using cannabis,
  • report using cannabis (no more than 2x in last month and no more than 100 lifetime use episodes)
  • meet DSM-5 criteria for PTSD w/ Sx of at least 6 months duration

Exclusion criteria

  • urine drug screen positive for any other drugs
  • systolic/diastolic BP >140/90 mmHg?
  • any clinically significant medical problems,
  • any current or past serious psychotic or bipolar disorder diagnosis as determined by SCID-5
  • at immediate high risk for suicide based on the C-SSRS
  • current SUD other than Nicotine Use Disorder and Alcohol Use Disorder (mild or moderate)
  • pregnancy, lactating
  • unable to provide informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

500 participants in 4 patient groups

THC Group
Experimental group
Description:
Cannabis with 2.5 mg THC; up to a maximum of 5 doses/day (max dose = 12.5 mg THC)
Treatment:
Drug: Tetrahydrocannabinol
CBD Group
Experimental group
Description:
Cannabis with 2.5 mg CBD; up to a maximum of 5 doses/day (max dose = 12.5 mg CBD)
Treatment:
Drug: Cannabidiol
THC & CBD Group
Experimental group
Description:
Cannabis with 2.5 mg THC and 2.5 mg CBD; up to a maximum of 5 doses/day (max doses = 12.5 mg THC and 12.5 mg CBD)
Treatment:
Drug: Tetrahydrocannabinol
Drug: Cannabidiol
Placebo Group
Active Comparator group
Description:
Cannabis with <1mg THC and <1mg CBD; up to a maximum of 5 doses/day (max dose = <5 mg THC and <5 mg CBD)
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Nareen Sadik, B.S.; Leslie Lundahl, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems